Search results
Author(s):
Camilla Andersen
Added:
8 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
Obesity is a primary risk factor for dyslipidaemia and cardiovascular disease (CVD), but the mechanisms linking weight gain to lipid metabolism are not fully understood. A new study suggests that in a specific genetic form of obesity caused by melanocortin 4 receptor (MC4R) deficiency, individuals may have a more favourable cardiometabolic profile despite their higher body weight.¹This multi-part…
View more
John Silberbauer
Author
UPDATE Trial: Minimally Processed Diet Superior for Weight Loss Within Healthy Eating Guidelines
Added:
10 months ago
Source:
Radcliffe CVRM
News
Author(s):
Pam Taub
Added:
1 year ago
Time-restricted eating in comparison to standard of care for patients with metabolic syndrome caused a reduction in hemoglobin A1C, LDL cholesterol, and body fat. What do these benefits suggest for the future of metabolic syndrome management?In this short interview, Dr Pam Taub (UC San Diego Health, San Diego, CA, US) advocates the use of life-style intervention in addition to pharmacotherapy…
View more
The Role of GLP-1 in Heart Failure
Author(s):
Amina Rakisheva
,
Anton Zatsarinnyy
Added:
4 months ago
Editorial
Liesbeth van Rossum
Research Area(s) / Expertise:
Job title: Professor, Obesity and Stress Hormone Research
Author
Dirk Müller-Wieland
Research Area(s) / Expertise:
Job title: Professor of Endocrinology, Metabolism and Diabetes
Author
Frédéric Sacher
Job title: Professor
Author
Eva Gerdts
Research Area(s) / Expertise:
Job title: Chief of the Non-invasive Cardiac Imaging Unit
Author